The mother The maternal mortality, from epilepsy, during pregnancy is low (approximately one fatality per year in England and Wales) but the number has remained steady in the last 50 years and, as other causes of maternal fatality have reduced, that occurring in women with epilepsy has become more prominent. As these fatalities occur as a result of accidents such as asphyxiation at the time of a generalised seizure, those treating pregnant women with epilepsy are likely to continue to seek the best possible control of the seizures with appropriate anticonvulsant therapy and to be wary of any drug reduction (even though it might benefit the fetus).
The pregnant woman with epilepsy is even more likely to become anaemic as a result of folic acid deficiency than someone who is not taking anticonvulsants; this is because most anticonvulsant drugs act as antagonists to folic acid. Although there is a slight worry that folate supplement may interfere with anticonvulsant metabolism,8 for instance by lowering the serum phenytoin concentration, this is neither serious enough nor common enough to contradict the advice that a small folate supplement (in the range 100-1000 pig) be given each day to all women of childbearing age who take anticonvulsants regularly, and that it be continued throughout pregnancy. 9 Vitamin D deficiency is a potential risk for women, and their fetuses, who are receiving long term phenytoin treatment. Phenytoin induces the production of enzymes that hydrolyse vitamin D, therefore, women receiving regular phenytoin should receive supplementary vitamin D throughout pregnancy.
The risk of complications of pregnancy in a woman with epilepsy is no greater than in a woman without epilepsy, though reports suggest that obstetric intervention, in the form of induction of labour and instrumental delivery, tends to be more prevalent when the mother has epilepsy (without there necessarily being good reason for such intervention).'0 The chance of spontaneous abortion or of multiple birth is not great, nor is there an increased risk of toxaemia. "l 4 Once it was realised that the coagulation defect was similar to that found in vitamin K defi-ciency it became possible to prevent and treat the coagulation abnormality. '5 16 The mother had severe generalised epilepsyfor which she usually received 300 mg ofphenytoin and 180 mg of phenobarbitone each day. In early pregnancy she had severe hyperemesis and daily grand mal seizwres.
The baby had cleft lip andpalate, trigonocephaly, minor abnormalities ofthe hand bones and nails, and divarication of the rectus abdominal muscles.
ings to those from more than 20 large retrospective studies in showing that children of epileptic mothers have over twice as many major congenital malformations as children of mothers without epilepsy.'8 Therefore if a mother has epilepsy, and is taking anticonvulsant drugs, the chance of her having a child with a major congenital abnormality is just over 6%. Clefts of the lip and palate are particularly likely (10 times more likely than in the general population) and congenital heart disease four times more likely. ' Reviewing the trials and the published case reports the oxazolidinedione drugs, troxidone (trimethadione) and paramethadione, seem to have been implicated particularly often. These reports were one of the factors leading to their increasingly restricted use for women of childbearing age. Reviewing all the surveys, phenytoin seems to have been blamed more often for congenital abnormality than most other anticonvulsants. It is difficult to know how much that results from its widespread use at a time when there were fewer effective anticonvulsants available. However, the impression remains that the hydantoin group of drugs may be more damaging than several other anticonvulsants. It should be born in mind that the congenital abnormalities with which hydantoins are associated (clefts of the lip and palate and congenital heart disease) usually are correctable by surgery. Rather more worrying are the isolated reports of neuroblastoma occurring in children who have been exposed to phenytoin in utero. 2224 Of the more recent anticonvulsants, major concern surrounds sodium valproate. Ten years ago it was regarded as completely safe in pregnancy but there is now clear evidence of its association with neural tube defects.25 The International Clearing House for Birth Defects monitoring systems suggest that the risk for a mother with epilepsy, taking sodium valproate during pregnancy, of having a child with spina bifida is approximately 1-2% compared with the risk of 0-06% for a woman who neither has epilepsy nor is receiving anticonvulsants.26 27 As, with appropriate counselling and screening for neural tube defects in the first trimester of pregnancy, such abnormal babies may be aborted, there are those who feel that the therapeutic efficacy of sodium valproate for specific patterns of epilepsy, such as juvenile myoclonic seizures, justifies its continued use in women of childbearing age providing that the risks and the options are discussed with the mothers. There are also reports that the offspring of such mothers have long term neurodevelopmental problems. This is a particularly difficult area to evaluate because of the different genetic, social, and environmental factors that contribute to a child's development. It is a sad fact that many children whose parents have severe epilepsy live in a disadvantaged environment.
For many years carbamazepine was considered extremely safe but the report from California last year of children identified both retrospectively and prospectively after exposure to carbamazepine in utero yielded the familiar pattern of minor craniofacial defects, fingernail hypoplasia, and neurodevelopmental delay that has been reported so often in the past with other anticonvulsant drugs.28 Benzodiazepines are less likely to be used as mainstay therapeutic treatment for epilepsy but, when they are taken regularly throughout pregnancy, they too probably increase the chance of a baby with dysmorphic features and developmental delay. 29 Several studies suggest that abnormalities are more likely if more than one anticonvulsant is used or if particularly large doses are taken. '8 The teratogenic effect The many large surveys revealing the increased incidence of congenital abnormalities in the infants of mothers who took anticonvulsants could not include a similar number of mothers with epilepsy who were not receiving anticonvulsants. Thus there has always been difficulty in establishing, with certainty, that it is the anticonvulsant drugs that are associated with fetal abnormality rather than epilepsy. Fifteen retrospective comparative studies did not find an increase in the incidence of congenital malformation in epileptic mothers who did not receive anticonvulsant drugs compared with the general population. 8 However, it can be presumed that woman with epilepsy, who are not taking anticonvulsant drugs, have much less severe epilepsy than those receiving anticonvulsant drugs, and therefore there remains the possibility that severe epilepsy itself is associated with congenital abnormality.
People with epilepsy are more prone to certain congenital abnormalities: cleft lip and palate and congenital heart disease, which itself is preferentially associated with clefts.30 31 However, that association is not strong and cannot account for the more than twofold increase in congenital abnormalities in babies born to mothers with epilepsy.
Moreover, two studies have shown that the children of men with epilepsy do not have an increased rate of severe congenital malformation, or of facial clefts, compared with the children of men in the general population.32 33 
